Enhanced nicotinic receptor function and drug abuse vulnerability.
In animals and humans, vulnerability to drug abuse varies among individuals. Animals that display high activity levels in a novel environment are more likely to self-administer psychostimulant drugs, including nicotine, cocaine, amphetamine, and morphine. Recent reports from behavioral studies indicate that nicotinic acetylcholine receptor (nAChR) activity contributes to the rewarding effects of several different addictive drugs. Thus, we hypothesized that differences in nAChR activity may contribute to the predisposition to drug self-administration. After screening of adult rats (>60 d postnatal) for the behavioral response to a novel environment, electrophysiological measures of nAChR function were conducted in brain slices that included the mesoaccumbens dopamine neurons of the ventral tegmental area (VTA). We found a positive correlation between the response to novelty and nAChR function in each assay conducted, including nAChR modulation of glutamatergic and GABAergic synaptic inputs to VTA dopamine neurons, as well as somatic nAChR responses of VTA neurons. The response to novelty and sensitivity to addictive drugs are positively correlated with the hormonal response to stress. Consistent with this observation, we found enhanced nAChR responses in vitro after a 48 h corticosterone treatment and in vivo after 48 h of repeated stress. Each of these effects was inhibited by RU486 (11beta-[p-(dimethylamino)phenyl]-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one) pretreatment, suggesting a steroid hormone receptor-dependent process. These findings suggest that differences in nAChR function within the mesoaccumbens dopamine system may contribute to individual differences in drug abuse vulnerability and that these are likely attributable to differences in stress hormone levels.
Fagen
Zara M
ZM
Committee on Neurobiology, University of Chicago, Chicago, Illinois 60637, USA.
Mitchum
Robert
R
Vezina
Paul
P
McGehee
Daniel S
DS
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D001640:Bicuculline / Q000494:pharmacology; D002478:Cells, Cultured; D003345:Corticosterone / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D004558:Electric Stimulation / Q000379:methods; D006727:Hormone Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D015735:Mifepristone / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology; D018408:Patch-Clamp Techniques / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D011978:Receptors, Nicotinic / Q000502:physiology*; D013223:Statistics as Topic; D013312:Stress, Physiological / Q000503:physiopathology; D017557:Ventral Tegmental Area / Q000166:cytology
D006727:Hormone Antagonists; D018722:Nicotinic Agonists; D011978:Receptors, Nicotinic; D015735:Mifepristone; D009538:Nicotine; D004298:Dopamine; D003345:Corticosterone; D001640:Bicuculline
J Neurosci. 2005 Jun 8;25(23):5563-72
15944384
Neuron. 2000 Aug;27(2):349-57
10985354
Nature. 1997 Nov 27;390(6658):401-4
9389479
J Comp Neurol. 2006 Feb 20;494(6):863-75
16385486
NIDA Res Monogr. 1998 Mar;169:105-33
9686413
J Neurobiol. 2002 Dec;53(4):606-17
12436424
Synapse. 1991 Oct;9(2):121-8
1821483
Arch Biochem Biophys. 2001 Oct 15;394(2):145-50
11594726
J Pharmacol Exp Ther. 1998 Oct;287(1):72-80
9765324
Eur J Neurosci. 1998 Nov;10(11):3565-71
9824469
Brain Res. 1991 Jun 21;552(1):67-76
1913182
Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2088-92
2006148
J Neurosci. 2006 Mar 8;26(10):2788-97
16525058
Psychopharmacology (Berl). 2001 Jan;153(3):380-8
11271411
Neuron. 2003 Feb 20;37(4):577-82
12597856
Neuron. 2002 Mar 14;33(6):905-19
11906697
J Comp Neurol. 1999 Jul 26;410(2):197-210
10414527
J Neurosci. 2001 Mar 15;21(6):1819-29
11245666
J Neurosci. 1996 Jan 15;16(2):714-22
8551354
J Neurosci. 2000 Jun 1;20(11):4226-32
10818158
Behav Brain Res. 2000 Aug;113(1-2):85-96
10942035
Mol Psychiatry. 2003 Mar;8(3):255-6
12660795
J Neurosci Methods. 1980 Dec;3(2):129-49
6110810
Pharmacol Biochem Behav. 1997 Aug;57(4):915-21
9259024
Science. 1989 Sep 29;245(4925):1511-3
2781295
J Neurosci. 2002 Jun 1;22(11):4654-62
12040071
Brain Res. 1996 Oct 14;736(1-2):61-7
8930309
J Pharmacol Exp Ther. 1997 Jun;281(3):1401-7
9190876
J Physiol. 2006 Dec 15;577(Pt 3):907-24
16959856
Steroids. 1999 Jan-Feb;64(1-2):83-91
10323676
Eur J Neurosci. 2002 Aug;16(3):387-94
12193179
Neuropsychopharmacology. 2001 May;24(5):576-89
11282258
Psychopharmacology (Berl). 2001 Nov;158(2):175-80
11702091
Nature. 1998 Jan 8;391(6663):173-7
9428762
Neuropharmacology. 2000 Oct;39(13):2740-55
11044744
J Neurosci. 2001 Mar 1;21(5):1452-63
11222635
J Neurosci. 2002 Apr 15;22(8):3269-76
11943828
Science. 1997 Oct 3;278(5335):52-8
9311926
J Comp Neurol. 2005 Mar 7;483(2):217-35
15678476